Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Riluzole
Drug ID BADD_D01942
Description A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
Indications and Usage For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
Marketing Status approved; investigational
ATC Code N07XX02
DrugBank ID DB00740
KEGG ID D00775
MeSH ID D019782
PubChem ID 5070
TTD Drug ID D0H0KB
NDC Product Code 68462-381; 70510-2201; 42291-775; 0378-4145; 62756-538; 67877-286; 69076-200; 63278-1076; 65129-1011; 70515-700; 65977-0045; 66039-812
UNII 7LJ087RS6F
Synonyms Riluzole | 2-Amino-6-trifluoromethoxybenzothiazole | 2 Amino 6 trifluoromethoxybenzothiazole | Rilutek | RP-54274 | RP 54274 | RP54274 | PK-26124 | PK 26124 | PK26124
Chemical Information
Molecular Formula C8H5F3N2OS
CAS Registry Number 1744-22-5
SMILES C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Faecaloma07.01.03.004--Not Available
Faecalith07.01.03.007--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.002100%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000538%
Major depression19.15.01.003--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Blood bilirubin abnormal13.03.04.016--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Prostate cancer21.04.02.002; 16.25.01.001--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Embolism24.01.01.009--
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction15.05.06.006; 17.01.02.031--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.004307%
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages